nisoldipine has been researched along with Blood Pressure, High in 121 studies
Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.
nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.
methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.
| Excerpt | Relevance | Reference |
|---|---|---|
| ": Thirty-seven patients with essential hypertension were randomized to receive telmisartan, the calcium channel blocker nisoldipine, or their combination for 6 weeks in a prospective, parallel group study." | 9.12 | Telmisartan improves endothelial function in patients with essential hypertension. ( Appel, D; Benndorf, RA; Böger, RH; Maas, R; Schwedhelm, E; Wenzel, UO, 2007) |
| "This study evaluates the efficacy of the new dihydropyridine calcium antagonist nisoldipine extended-release (ER) compared to amlodipine on ambulatory and clinic blood pressures (BP) and heart rates in African American patients with hypertension." | 9.10 | Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension. ( Ferdinand, K; Noveck, RJ; Saunders, E; White, WB, 2003) |
| "The efficacy and safety of nisoldipine-extended release (ER) and amlodipine were compared in a 6-week multicenter, randomized, double-blind, double-dummy, parallel group, titration-to-effect trial in patients with stage 1 to 2 systemic hypertension (90 to 109 mm Hg diastolic blood pressure [BP]) and chronic stable angina pectoris." | 9.10 | Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris. ( Bittar, N; Cooper-DeHoff, RM; Hutchinson, HG; Koren, M; Michelson, EL; Minkwitz, MC; Pepine, CJ; Thadani, U; Weiss, RJ, 2003) |
| "To compare 24-hour blood pressure control and adverse effects in patients with essential hypertension who were switched from amlodipine to nisoldipine." | 9.09 | Comparison of 24-hour blood pressure profiles in patients with hypertension who were switched from amlodipine to nisoldipine. ( Hilleman, DE; Lenz, TL; Wurdeman, RL, 2001) |
| "A single-center, prospective double-blind randomized trial was conducted to compare the efficacy and safety of the calcium channel blocker nisoldipine in a sustained release coat-core formulation (CC), titrated from 10 mg to 40 mg daily, with the angiotensin converting enzyme inhibitor enalapril, titrated from 10 to 40 mg daily, in the treatment of black South African patients with severe hypertension (sitting diastolic blood pressure [DBP] between 115 and 140 mm Hg, confirmed by 24-h ambulatory blood pressure monitoring)." | 9.09 | Antihypertensive monotherapy with nisoldipine CC is superior to enalapril in black patients with severe hypertension. ( Candy, G; Radevski, I; Sareli, P; Sathekge, S; Skudicky, D; Strugo, V, 1999) |
| "The efficacy and safety of nisoldipine CC and felodipine were compared in a multicentre, randomised, double-blind, trial in patients with mild-to-moderate hypertension (n = 229)." | 9.08 | A comparison of nisoldipine coat-core and felodipine in the treatment of mild-to-moderate hypertension. ( Hoglund, C; Hutchinson, HG, 1998) |
| "Twenty-four patients completed a dose ranging study of the effect of nisoldipine as monotherapy in the treatment of hypertension." | 9.08 | Comparison of once daily and twice daily nisoldipine as monotherapy in essential hypertension. ( Davidson, C; Davidsson, GK; Edwards, JS, 1996) |
| "In this population of patients with diabetes and hypertension, we found a significantly higher incidence of fatal and nonfatal myocardial infarction among those assigned to therapy with the calcium-channel blocker nisoldipine than among those assigned to receive enalapril." | 9.08 | The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. ( Biggerstaff, SL; Estacio, RO; Gifford, N; Hiatt, WR; Jeffers, BW; Schrier, RW, 1998) |
| "The efficacy and safety of nisoldipine CC and lisinopril were compared in 278 patients with mild to moderate systemic hypertension in a double-blind, placebo run-in trial." | 9.08 | Nisoldipine CC and lisinopril alone or in combination for treatment of mild to moderate systemic hypertension. Canadian Nisoldipine CC Hypertension Trial Group. ( Fodor, JG; Ruddy, TD, 1997) |
| "Our objective was to compare the effect of a long-acting calcium antagonist (nisoldipine) versus an ACE inhibitor (lisinopril) on albuminuria, arterial blood pressure, and glomerular filtration rate (GFR) in hypertensive IDDM patients with diabetic nephropathy." | 9.08 | Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. ( Boelskifte, S; Jensen, BR; Nielsen, FS; Parving, HH; Rossing, P; Tarnow, L, 1997) |
| "A comparative, randomized and cross clinical trial between nisoldipine and alpha-methyldopa in 50 aged patients with isolated systolic hypertension during 12 weeks." | 9.07 | [A comparative study of nisoldipine and alpha-methyldopa in aged patients with isolated systolic hypertension]. ( Guillén Llera, F; Reuss, JM; Sagués, F; Tobares, N, 1991) |
| "In 80 patients with moderate hypertension the effects of nisoldipine 10 mg b." | 9.07 | The effects of nisoldipine, diltiazem, nifedipine, and verapamil on hemodynamic parameters and red blood cells-platelet interactions in patients with arterial hypertension. ( Belousov, Y; Kushnaryov, V, 1991) |
| "The calcium antagonist nisoldipine (Bayer-Miles) was given orally (20 mg, 8-hourly) in the management of 12 selected cases of severe postpartum pregnancy-induced hypertension (PIH)." | 9.07 | Nisoldipine--a new orally administered calcium antagonist used in the treatment of severe postpartum pregnancy-induced hypertension. Preliminary results. ( Belfort, MA; Kirshon, B, 1992) |
| "The relationship between the age and the clinical efficacy of a new long acting calcium entry blocker, nisoldipine, was investigated in essential hypertension using two double blind group studies, in which nifedipine or atenolol was used as a control drug." | 9.06 | [Age and efficacy of new long acting calcium blocker, nisoldipine, is essential hypertension]. ( Kaneko, Y; Kuwajima, I; Takeda, T, 1989) |
| "The antihypertensive effects of nisoldipine, a calcium channel blocker, and atenolol, a beta-adrenergic blocker, were compared in patients with mild or moderate essential hypertension." | 9.06 | Comparison of nisoldipine and atenolol in the treatment of essential hypertension. ( Fukuyama, M; Okabayashi, H; Takahashi, H; Yoneda, S; Yoshimura, M, 1989) |
| "Nisoldipine coat-core (CC), a 1,4-dihydropyridine calcium antagonist, is indicated for the treatment of hypertension and may be used alone or in combination with other antihypertensive agents." | 8.84 | Pharmacologic agents in the management of hypertension--nisoldipine coat-core. ( White, WB, 2007) |
| "Nisoldipine coat core (CC) is a long-acting formulation of the dihydropyridine calcium channel blocker nisoldipine, suitable for once-daily administration in the treatment of patients with hypertension." | 8.79 | Nisoldipine CC: clinical experience in hypertension. ( Heinig, R; Langan, J; Rodríguez-Mañas, L; Sareli, P, 1997) |
| "The effects of the long-acting dihydropyridine calcium antagonist nisoldipine coat core (CC) have been investigated in > 3,500 patients with angina pectoris, hypertension, and ischemic ventricular dysfunction." | 8.79 | Efficacy and safety of nisoldipine coat core in the management of angina pectoris, systemic hypertension, and ischemic ventricular dysfunction. ( Lewis, BS, 1995) |
| "Nisoldipine coat-core is a long-acting formulation of the dihydropyridine calcium antagonist (calcium channel blocker) nisoldipine, suitable for once daily administration in the treatment of patients with hypertension." | 8.79 | Nisoldipine coat-core. A review of its pharmacology and therapeutic efficacy in hypertension. ( Faulds, D; Plosker, GL, 1996) |
| "The acute hemodynamic effects of nisoldipine (Bay K552) in patients with essential hypertension were studied using nuclear ventriculography." | 7.69 | Cardiovascular effects of nisoldipine in essential hypertension. ( Battler, A; Blau, A; Eliahou, HE; Herz, I; Herzog, D; Schechter, P, 1994) |
| "The acute and chronic hemodynamic effects of nisoldipine were studied in 19 patients (17 men, 2 women; mean age 43 years) with essential hypertension at rest supine and sitting and during steady state 100 W bicycle exercise." | 7.67 | Central hemodynamic effects at rest and during exercise of acute and chronic treatment with nisoldipine in essential hypertension. ( Haugland, H; Lund-Johansen, P; Omvik, P, 1987) |
| ") was evaluated as a replacement therapy for long-acting nifedipine (40-120 mg/day) in 21 patients with severe hypertension, who were resistant to or intolerant of nifedipine." | 7.67 | Nisoldipine: a replacement therapy for nifedipine in the treatment of severe hypertension. ( Grossman, E; Rosenthal, T, 1988) |
| "The effect of long-term treatment with the calcium antagonist nisoldipine on development of hypertension, cardiac hypertrophy, and plasma levels of atrial natriuretic peptides (ANP) was determined in spontaneously hypertensive rats (SHR) and Wistar-Kyoto rats (WKY) of the same age." | 7.67 | Role of nisoldipine on blood pressure, cardiac hypertrophy, and atrial natriuretic peptides in spontaneously hypertensive rats. ( Hirth, C; Kazda, S; Morich, F; Stasch, JP, 1987) |
| "The effect of daily treatment (sometimes interrupted) with the calcium blocker nisoldipine at two different dose levels, one double the other, on the development of spontaneous hypertension in the rat was evaluated." | 7.66 | Prevention of spontaneous and glucocorticoid hypertension in rats by nisoldipine. ( Hall, CE; Hungerford, S, 1983) |
| " The regimen was started at low dose with an increase of dosage after 3 weeks of treatment." | 6.73 | Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension. ( Appel, D; Bajcetic, M; Benndorf, RA; Böger, RH; Maas, R; Riekhof, D; Schulze, F; Schwedhelm, E, 2007) |
| "Hypertension is a cardiovascular risk factor commonly associated with insulin resistance, the metabolic syndrome, and type 2 diabetes mellitus." | 6.72 | Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. ( Appel, D; Benndorf, RA; Böger, RH; Maas, R; Rudolph, T; Schulze, F; Schwedhelm, E; Silberhorn, E, 2006) |
| " Blood pressure measurements (supine, standing, diastolic, and systolic) were taken at trough plasma levels, 24 h after previous dosing at 2-week intervals throughout the study." | 6.68 | Efficacy and tolerability of nisoldipine coat-core formulation in the treatment of essential hypertension: The South African Multicenter ANCHOR Study. Ambulatory Nisoldipine Coat-Core Hypertension Outpatient Response (ANCHOR) Investigators. ( Luus, HG; Müller, FO; Myburgh, DP; Opie, LH; Rosendorff, C; Sareli, P; Seedat, YK; Weich, DJ, 1997) |
| "Nisoldipine, which has a higher coronary vascular selectivity and less negative inotropism than nifedipine, is as effective and as well tolerated as nifedipine in patients whose hypertension is inadequately controlled on atenolol." | 6.67 | Comparison of nisoldipine and nifedipine as additional treatment in hypertension inadequately controlled by atenolol. ( Earle, KA; Hoffbrand, BI; Nievel, JG; Restrick, LJ; Simmonds, NJ, 1993) |
| " Both nisoldipine and the diuretic had a flat dose-response curve." | 6.66 | Monotherapy with the calcium channel antagonist nisoldipine for systemic hypertension and comparison with diuretic drugs. ( Daniels, AR; Opie, LH, 1987) |
| "Nisoldipine was well tolerated and an effective antihypertensive agent when administered over a period of 6 weeks." | 6.66 | The effect of nisoldipine on renal function in the long-term treatment of hypertension in patients with and without renal impairment. ( Brownjohn, AM; Davies, JA; Hainsworth, R; Martin, PG; Prentice, CR; Turney, JH; Wahbha, MM; Wilson, J, 1989) |
| "We have assessed the efficacy and tolerance of Nifedipine twice daily and Nisoldipine once daily, both alone and in combination with a beta-blocker in 171 essential hypertensives in a randomized parallel comparison fashion." | 6.66 | The efficacy and tolerability of nifedipine (NIF) and nisoldipine (NIS) both alone and combined with a beta-blocker in patients with essential hypertension: a multicenter, parallel-group study. ( Rosenfeld, JB; Zabludowski, J, 1989) |
| "In patients with chronic renal failure, decrement in BP was 25/16 mmHg (systolic and diastolic BP, respectively)." | 6.65 | [Hypotensive properties of nisoldipine. Comparative study in essential, renal and renovascular hypertension]. ( Breuer, G; Kaufmann, W; Wambach, G, 1984) |
| "Nisoldipine is a second-generation dihydropyridine calcium channel blocker (CCB)." | 6.40 | Nisoldipine CC: efficacy and tolerability in hypertension and ischemic heart disease. ( Fodor, JG, 1997) |
| "Nisoldipine is an orally administered calcium entry blocking drug structurally related to nifedipine." | 6.37 | Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders. ( Friedel, HA; Sorkin, EM, 1988) |
| " Response was assessed by cuff pressures taken 24 h after dosing at fortnightly intervals, and if not controlled (less than 150/95 or at least 10 mm Hg reduction in diastolic BP) the dose was increased to 20 mg." | 5.28 | Once daily nisoldipine in hypertension: cuff and ambulatory intra-arterial blood pressure. ( Brigden, G; Caruana, M; Heber, M; Lahiri, A; Raftery, EB, 1989) |
| "The findings demonstrate that nisoldipine and olmesartan both improve FMD in patients with essential hypertension." | 5.16 | Effect of nisoldipine and olmesartan on endothelium-dependent vasodilation in essential hypertensive patients. ( He, WY; Lv, QZ; Wei, D, 2012) |
| ": Thirty-seven patients with essential hypertension were randomized to receive telmisartan, the calcium channel blocker nisoldipine, or their combination for 6 weeks in a prospective, parallel group study." | 5.12 | Telmisartan improves endothelial function in patients with essential hypertension. ( Appel, D; Benndorf, RA; Böger, RH; Maas, R; Schwedhelm, E; Wenzel, UO, 2007) |
| " To investigate whether antihypertensive treatment has an influence on the number of circulating EPCs, patients with essential hypertension were treated either with the angiotensin receptor antagonist telmisartan, the calcium channel blocker nisoldipine, or their combination for 6 weeks." | 5.12 | Mobilization of putative high-proliferative-potential endothelial colony-forming cells during antihypertensive treatment in patients with essential hypertension. ( Appel, D; Benndorf, RA; Böger, R; Gehling, UM; Hossfeld, DK; Maas, R; Rogiers, X; Schlagner, K; Schwedhelm, E; Silberhorn, E, 2007) |
| "The efficacy and safety of nisoldipine-extended release (ER) and amlodipine were compared in a 6-week multicenter, randomized, double-blind, double-dummy, parallel group, titration-to-effect trial in patients with stage 1 to 2 systemic hypertension (90 to 109 mm Hg diastolic blood pressure [BP]) and chronic stable angina pectoris." | 5.10 | Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris. ( Bittar, N; Cooper-DeHoff, RM; Hutchinson, HG; Koren, M; Michelson, EL; Minkwitz, MC; Pepine, CJ; Thadani, U; Weiss, RJ, 2003) |
| "This study evaluates the efficacy of the new dihydropyridine calcium antagonist nisoldipine extended-release (ER) compared to amlodipine on ambulatory and clinic blood pressures (BP) and heart rates in African American patients with hypertension." | 5.10 | Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension. ( Ferdinand, K; Noveck, RJ; Saunders, E; White, WB, 2003) |
| "Nisoldipine (N) is a dihydropyridine calcium antagonist marketed as a racemic mixture and used for the treatment of hypertension." | 5.10 | Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ( Coelho, EB; Dos Santos, NA; Geleilete, TJ; Lanchote, VL; Marques, MP, 2002) |
| "A single-center, prospective double-blind randomized trial was conducted to compare the efficacy and safety of the calcium channel blocker nisoldipine in a sustained release coat-core formulation (CC), titrated from 10 mg to 40 mg daily, with the angiotensin converting enzyme inhibitor enalapril, titrated from 10 to 40 mg daily, in the treatment of black South African patients with severe hypertension (sitting diastolic blood pressure [DBP] between 115 and 140 mm Hg, confirmed by 24-h ambulatory blood pressure monitoring)." | 5.09 | Antihypertensive monotherapy with nisoldipine CC is superior to enalapril in black patients with severe hypertension. ( Candy, G; Radevski, I; Sareli, P; Sathekge, S; Skudicky, D; Strugo, V, 1999) |
| "To compare 24-hour blood pressure control and adverse effects in patients with essential hypertension who were switched from amlodipine to nisoldipine." | 5.09 | Comparison of 24-hour blood pressure profiles in patients with hypertension who were switched from amlodipine to nisoldipine. ( Hilleman, DE; Lenz, TL; Wurdeman, RL, 2001) |
| " Using 24-h ambulatory monitoring, we compared the effects of morning and evening dosing of the long-acting dihydropyridine calcium channel blocker, nisoldipine extended-release (ER), on circadian blood pressure (BP) and heart rate in patients with mild-to-moderate hypertension." | 5.09 | Differential effects of morning and evening dosing of nisoldipine ER on circadian blood pressure and heart rate. ( Hutchinson, HG; Johnson, RB; Mansoor, GA; Noveck, R; Pickering, TG; Vidt, DG; White, WB, 1999) |
| "3 years of follow-up of 470 patients with hypertension and evaluates the effects of intensive and moderate blood pressure therapy using nisoldipine versus enalapril as the initial antihypertensive medication for nephropathy, retinopathy, and neuropathy." | 5.09 | Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. ( Estacio, RO; Gifford, N; Jeffers, BW; Schrier, RW, 2000) |
| "The efficacy and safety of nisoldipine CC and lisinopril were compared in 278 patients with mild to moderate systemic hypertension in a double-blind, placebo run-in trial." | 5.08 | Nisoldipine CC and lisinopril alone or in combination for treatment of mild to moderate systemic hypertension. Canadian Nisoldipine CC Hypertension Trial Group. ( Fodor, JG; Ruddy, TD, 1997) |
| "The efficacy and safety of nisoldipine CC and felodipine were compared in a multicentre, randomised, double-blind, trial in patients with mild-to-moderate hypertension (n = 229)." | 5.08 | A comparison of nisoldipine coat-core and felodipine in the treatment of mild-to-moderate hypertension. ( Hoglund, C; Hutchinson, HG, 1998) |
| "Nisoldipine, a calcium antagonist of the dihydropyridine class, has been used in the treatment of hypertension and angina pectoris." | 5.08 | Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form. ( Adelmann, H; Ahr, G; Heinig, R; Kuhlmann, J; Schaefer, HG; Tetzloff, W, 1997) |
| "Our objective was to compare the effect of a long-acting calcium antagonist (nisoldipine) versus an ACE inhibitor (lisinopril) on albuminuria, arterial blood pressure, and glomerular filtration rate (GFR) in hypertensive IDDM patients with diabetic nephropathy." | 5.08 | Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. ( Boelskifte, S; Jensen, BR; Nielsen, FS; Parving, HH; Rossing, P; Tarnow, L, 1997) |
| " We compared the effects of cilnidipine and another once-daily dihydropyridine calcium antagonist, nisoldipine, on 24-h blood pressure and heart rate in patients with essential hypertension." | 5.08 | Comparison between cilnidipine and nisoldipine with respect to effects on blood pressure and heart rate in hypertensive patients. ( Higashi, T; Ishimitsu, T; Matsuoka, H; Minami, J; Numabe, A, 1998) |
| "Twenty-four patients completed a dose ranging study of the effect of nisoldipine as monotherapy in the treatment of hypertension." | 5.08 | Comparison of once daily and twice daily nisoldipine as monotherapy in essential hypertension. ( Davidson, C; Davidsson, GK; Edwards, JS, 1996) |
| "In this population of patients with diabetes and hypertension, we found a significantly higher incidence of fatal and nonfatal myocardial infarction among those assigned to therapy with the calcium-channel blocker nisoldipine than among those assigned to receive enalapril." | 5.08 | The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. ( Biggerstaff, SL; Estacio, RO; Gifford, N; Hiatt, WR; Jeffers, BW; Schrier, RW, 1998) |
| "A comparative, randomized and cross clinical trial between nisoldipine and alpha-methyldopa in 50 aged patients with isolated systolic hypertension during 12 weeks." | 5.07 | [A comparative study of nisoldipine and alpha-methyldopa in aged patients with isolated systolic hypertension]. ( Guillén Llera, F; Reuss, JM; Sagués, F; Tobares, N, 1991) |
| "The antihypertensive effect of nisoldipine on ambulatory blood pressure was investigated using continuous noninvasive monitoring in 12 patients with moderate essential hypertension." | 5.07 | Effect of nisoldipine on ambulatory blood pressure under 24-hour noninvasive monitoring. ( Blau, A; Eliahou, HE; Herzog, D; Shechter, P, 1992) |
| "The calcium antagonist nisoldipine (Bayer-Miles) was given orally (20 mg, 8-hourly) in the management of 12 selected cases of severe postpartum pregnancy-induced hypertension (PIH)." | 5.07 | Nisoldipine--a new orally administered calcium antagonist used in the treatment of severe postpartum pregnancy-induced hypertension. Preliminary results. ( Belfort, MA; Kirshon, B, 1992) |
| "This randomized double-blind parallel group study characterized the pharmacokinetics of the calcium channel antagonist, nisoldipine (core-coat tablets), administered once daily for 7 days in doses of 5 mg (n = 12), 10 mg (n = 13), 20 mg (n = 12), and 30 mg (n = 11) to patients with mild to moderate hypertension." | 5.07 | Multiple dose pharmacokinetics of four different doses of nisoldipine in hypertensive patients. ( Allington, DR; Chandler, MH; Clifton, GD; Foster, TS; Harrison, MR; Lettieri, JT; Mazzu, AL; Thieneman, AC, 1992) |
| "In 80 patients with moderate hypertension the effects of nisoldipine 10 mg b." | 5.07 | The effects of nisoldipine, diltiazem, nifedipine, and verapamil on hemodynamic parameters and red blood cells-platelet interactions in patients with arterial hypertension. ( Belousov, Y; Kushnaryov, V, 1991) |
| "The effects of nisoldipine and slow release nifedipine on mild to moderate hypertension and glycaemic control were studied in 28 diabetic hypertensives, all except one of whom were non-insulin dependent." | 5.07 | Nifedipine and nisoldipine in hypertensive diabetics. ( Clarke, CW; Kubik, MM, 1991) |
| "Nisoldipine is a calcium antagonist of the dihydropyridine group under investigation for treatment of hypertension." | 5.07 | Responses to sympathetic stimulation and tilting during antihypertensive treatment with nisoldipine. ( Ferrara, LA; Pasanisi, F; Soro, S, 1991) |
| "The relationship between the age and the clinical efficacy of a new long acting calcium entry blocker, nisoldipine, was investigated in essential hypertension using two double blind group studies, in which nifedipine or atenolol was used as a control drug." | 5.06 | [Age and efficacy of new long acting calcium blocker, nisoldipine, is essential hypertension]. ( Kaneko, Y; Kuwajima, I; Takeda, T, 1989) |
| "The antihypertensive effects of nisoldipine, a calcium channel blocker, and atenolol, a beta-adrenergic blocker, were compared in patients with mild or moderate essential hypertension." | 5.06 | Comparison of nisoldipine and atenolol in the treatment of essential hypertension. ( Fukuyama, M; Okabayashi, H; Takahashi, H; Yoneda, S; Yoshimura, M, 1989) |
| "We have studied the effects of nisoldipine, a new calcium channel antagonist, on the renin-angiotensin-aldosterone system and on plasma catecholamines in 10 healthy volunteers and in 29 patients with primary essential hypertension." | 5.06 | Nisoldipine--effects on the renin-angiotensin-aldosterone system and catecholamines. Studies in normotensive and hypertensive subjects. ( Karlberg, BE; Ottosson, AM, 1990) |
| "Nisoldipine coat-core (CC), a 1,4-dihydropyridine calcium antagonist, is indicated for the treatment of hypertension and may be used alone or in combination with other antihypertensive agents." | 4.84 | Pharmacologic agents in the management of hypertension--nisoldipine coat-core. ( White, WB, 2007) |
| "Nisoldipine coat-core is a long-acting formulation of the dihydropyridine calcium antagonist (calcium channel blocker) nisoldipine, suitable for once daily administration in the treatment of patients with hypertension." | 4.79 | Nisoldipine coat-core. A review of its pharmacology and therapeutic efficacy in hypertension. ( Faulds, D; Plosker, GL, 1996) |
| "The effects of the long-acting dihydropyridine calcium antagonist nisoldipine coat core (CC) have been investigated in > 3,500 patients with angina pectoris, hypertension, and ischemic ventricular dysfunction." | 4.79 | Efficacy and safety of nisoldipine coat core in the management of angina pectoris, systemic hypertension, and ischemic ventricular dysfunction. ( Lewis, BS, 1995) |
| "Nisoldipine coat core (CC) is a long-acting formulation of the dihydropyridine calcium channel blocker nisoldipine, suitable for once-daily administration in the treatment of patients with hypertension." | 4.79 | Nisoldipine CC: clinical experience in hypertension. ( Heinig, R; Langan, J; Rodríguez-Mañas, L; Sareli, P, 1997) |
| "Doppler echocardiographic determination, left ventricular (LV) fractional shortening (FS), cardiac output (CO), diastolic function parameter (E/A ratio) and carotid artery pulse wave velocity and stiffness were evaluated in 36 patients with essential hypertension before and after nisoldipine treatment." | 3.69 | The effects of nisoldipine on carotid artery stiffness and left ventricular functions. ( Cin, VG; Dogan, A; Gokçin, A; Kozan, O; Tavli, T, 1995) |
| "The acute hemodynamic effects of nisoldipine (Bay K552) in patients with essential hypertension were studied using nuclear ventriculography." | 3.69 | Cardiovascular effects of nisoldipine in essential hypertension. ( Battler, A; Blau, A; Eliahou, HE; Herz, I; Herzog, D; Schechter, P, 1994) |
| "This study examined the protective effects of a calcium channel blocker, nisoldipine (NSL), against organ damage secondary to severe hypertension." | 3.69 | Benefits and demerits of antihypertensive therapy by high-dose calcium channel blocker in severely hypertensive rats. ( Ishimitsu, T; Ogawa, Y; Tsukada, H; Yagi, S, 1994) |
| " Cardiovascular responses to upright tilting were determined before and after treatment with the calcium antagonist, nisoldipine, in patients with essential hypertension and in patients of similar ages and similar degrees of hypertension complicated by renal impairment." | 3.68 | Cardiovascular responses to upright tilting in hypertensive patients, with and without renal impairment and before and following nisoldipine treatment. ( Hainsworth, R; Wahbha, MM; Wilson, J, 1990) |
| "Nifedipine and nisoldipine: (a) attenuate hypertension and decrease left ventricular mass in spontaneously hypertensive rats, but the associated decrease in myocyte size was not significant; (b) are cardioprotective as indicated by a significant decrease in the incidence of microscopic scarring; and (c) decrease the extent of reactive, both interstitial and perivascular, fibrosis normally found in untreated spontaneously hypertensive rats." | 3.68 | Cardiac structural remodelling after treatment of spontaneously hypertensive rats with nifedipine or nisoldipine. ( Campbell, SE; Kazda, S; Rakusan, K; Turek, Z, 1993) |
| "In six patients with essential hypertension, the pharmacokinetics of nisoldipine were investigated before, during, and after 4 weeks of treatment." | 3.67 | Pharmacokinetics and hemodynamic effects of long-term nisoldipine treatment in hypertensive patients. ( Breimer, DD; Danhof, M; Quekel, RP; van Brummelen, P; van Harten, J, 1989) |
| "The acute and chronic hemodynamic effects of nisoldipine were studied in 19 patients (17 men, 2 women; mean age 43 years) with essential hypertension at rest supine and sitting and during steady state 100 W bicycle exercise." | 3.67 | Central hemodynamic effects at rest and during exercise of acute and chronic treatment with nisoldipine in essential hypertension. ( Haugland, H; Lund-Johansen, P; Omvik, P, 1987) |
| " Calcium antagonists, including verapamil, are now used widely in the management of patients with hypertension." | 3.67 | Calcium antagonists and hypertension. ( Dillon, JS; Nayler, WG; Sturrock, WJ, 1988) |
| "The effect of long-term treatment with the calcium antagonist nisoldipine on development of hypertension, cardiac hypertrophy, and plasma levels of atrial natriuretic peptides (ANP) was determined in spontaneously hypertensive rats (SHR) and Wistar-Kyoto rats (WKY) of the same age." | 3.67 | Role of nisoldipine on blood pressure, cardiac hypertrophy, and atrial natriuretic peptides in spontaneously hypertensive rats. ( Hirth, C; Kazda, S; Morich, F; Stasch, JP, 1987) |
| ") was evaluated as a replacement therapy for long-acting nifedipine (40-120 mg/day) in 21 patients with severe hypertension, who were resistant to or intolerant of nifedipine." | 3.67 | Nisoldipine: a replacement therapy for nifedipine in the treatment of severe hypertension. ( Grossman, E; Rosenthal, T, 1988) |
| "The effect of daily treatment (sometimes interrupted) with the calcium blocker nisoldipine at two different dose levels, one double the other, on the development of spontaneous hypertension in the rat was evaluated." | 3.66 | Prevention of spontaneous and glucocorticoid hypertension in rats by nisoldipine. ( Hall, CE; Hungerford, S, 1983) |
| " The regimen was started at low dose with an increase of dosage after 3 weeks of treatment." | 2.73 | Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension. ( Appel, D; Bajcetic, M; Benndorf, RA; Böger, RH; Maas, R; Riekhof, D; Schulze, F; Schwedhelm, E, 2007) |
| "Hypertension is a cardiovascular risk factor commonly associated with insulin resistance, the metabolic syndrome, and type 2 diabetes mellitus." | 2.72 | Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. ( Appel, D; Benndorf, RA; Böger, RH; Maas, R; Rudolph, T; Schulze, F; Schwedhelm, E; Silberhorn, E, 2006) |
| " The effect of acute and chronic administration of nisoldipine (once and twice daily) was investigated in 17 elderly hypertensive patients." | 2.68 | The effect of age and liver disease on the pharmacokinetics of the calcium antagonist, nisoldipine. ( Davidson, C; Davidsson, GK; Edwards, JS, 1995) |
| " Blood pressure measurements (supine, standing, diastolic, and systolic) were taken at trough plasma levels, 24 h after previous dosing at 2-week intervals throughout the study." | 2.68 | Efficacy and tolerability of nisoldipine coat-core formulation in the treatment of essential hypertension: The South African Multicenter ANCHOR Study. Ambulatory Nisoldipine Coat-Core Hypertension Outpatient Response (ANCHOR) Investigators. ( Luus, HG; Müller, FO; Myburgh, DP; Opie, LH; Rosendorff, C; Sareli, P; Seedat, YK; Weich, DJ, 1997) |
| " A significant decrease in blood pressure was observed after consecutive dosing of nisoldipine compared to baseline values over 24 h in both groups." | 2.68 | Pharmacokinetics and pharmacodynamics of nisoldipine in hypertensive patients with normal and mild to moderate impaired renal function. ( Jinno, Y; Masumori, S; Minamisawa, K; Minamisawa, M; Nagasawa, T; Satta, H; Shionoiri, H; Takasaki, I; Takeda, K; Takizawa, T, 1995) |
| "Nisoldipine, which has a higher coronary vascular selectivity and less negative inotropism than nifedipine, is as effective and as well tolerated as nifedipine in patients whose hypertension is inadequately controlled on atenolol." | 2.67 | Comparison of nisoldipine and nifedipine as additional treatment in hypertension inadequately controlled by atenolol. ( Earle, KA; Hoffbrand, BI; Nievel, JG; Restrick, LJ; Simmonds, NJ, 1993) |
| "Nisoldipine was well tolerated and an effective antihypertensive agent when administered over a period of 6 weeks." | 2.66 | The effect of nisoldipine on renal function in the long-term treatment of hypertension in patients with and without renal impairment. ( Brownjohn, AM; Davies, JA; Hainsworth, R; Martin, PG; Prentice, CR; Turney, JH; Wahbha, MM; Wilson, J, 1989) |
| "The pharmacodynamic and pharmacokinetic profiles of nifedipine and nisoldipine were compared in a double blind, placebo-controlled study." | 2.66 | The pharmacodynamics and pharmacokinetics of a new calcium antagonist nisoldipine in normotensive and hypertensive subjects. ( Meredith, PA; Pasanisi, F; Reid, JL, 1985) |
| "We have assessed the efficacy and tolerance of Nifedipine twice daily and Nisoldipine once daily, both alone and in combination with a beta-blocker in 171 essential hypertensives in a randomized parallel comparison fashion." | 2.66 | The efficacy and tolerability of nifedipine (NIF) and nisoldipine (NIS) both alone and combined with a beta-blocker in patients with essential hypertension: a multicenter, parallel-group study. ( Rosenfeld, JB; Zabludowski, J, 1989) |
| " Both nisoldipine and the diuretic had a flat dose-response curve." | 2.66 | Monotherapy with the calcium channel antagonist nisoldipine for systemic hypertension and comparison with diuretic drugs. ( Daniels, AR; Opie, LH, 1987) |
| "In patients with chronic renal failure, decrement in BP was 25/16 mmHg (systolic and diastolic BP, respectively)." | 2.65 | [Hypotensive properties of nisoldipine. Comparative study in essential, renal and renovascular hypertension]. ( Breuer, G; Kaufmann, W; Wambach, G, 1984) |
| "Nisoldipine is a second-generation dihydropyridine calcium channel blocker (CCB)." | 2.40 | Nisoldipine CC: efficacy and tolerability in hypertension and ischemic heart disease. ( Fodor, JG, 1997) |
| " Nisoldipine CC should not be used in patients with liver cirrhosis, though dosage adjustments in patients with renal impairment are not necessary." | 2.40 | Clinical pharmacokinetics of nisoldipine coat-core. ( Heinig, R, 1998) |
| "Nisoldipine CC is an effective antihypertensive agent in both black and nonblack South African ethnic groups." | 2.40 | What does nisoldipine coat core (CC) add to current therapy that is clinically meaningful? ( Opie, LH, 1997) |
| "Nisoldipine is a new calcium-channel blocker of the dihydropyridine subclass, with a chemical structure similar to nifedipine." | 2.38 | Nisoldipine: a new dihydropyridine calcium-channel blocker. ( Frishman, W; Heiman, M; Mitchell, J, 1993) |
| "Nisoldipine is an orally administered calcium entry blocking drug structurally related to nifedipine." | 2.37 | Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders. ( Friedel, HA; Sorkin, EM, 1988) |
| " Response was assessed by cuff pressures taken 24 h after dosing at fortnightly intervals, and if not controlled (less than 150/95 or at least 10 mm Hg reduction in diastolic BP) the dose was increased to 20 mg." | 1.28 | Once daily nisoldipine in hypertension: cuff and ambulatory intra-arterial blood pressure. ( Brigden, G; Caruana, M; Heber, M; Lahiri, A; Raftery, EB, 1989) |
| "3-3 mg/kg), dose-response curves of the antihypertensive effect did not change and body weight gain was equal to that of the vehicle-treated group." | 1.28 | Antihypertensive effects of MPC-1304, a novel calcium antagonist, in experimental hypertensive rats and dogs. ( Haruno, A; Kanda, A; Miyake, H; Nagasaka, M, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 32 (26.45) | 18.7374 |
| 1990's | 69 (57.02) | 18.2507 |
| 2000's | 17 (14.05) | 29.6817 |
| 2010's | 2 (1.65) | 24.3611 |
| 2020's | 1 (0.83) | 2.80 |
| Authors | Studies |
|---|---|
| Mundada, VP | 1 |
| Patel, MH | 1 |
| Mundada, PK | 1 |
| Sawant, KK | 1 |
| Tajani, AH | 1 |
| Nesbitt, SD | 1 |
| Ruggenenti, P | 1 |
| Cravedi, P | 1 |
| Remuzzi, G | 1 |
| Wei, D | 1 |
| He, WY | 1 |
| Lv, QZ | 1 |
| Marques, MP | 1 |
| Coelho, EB | 1 |
| Dos Santos, NA | 1 |
| Geleilete, TJ | 1 |
| Lanchote, VL | 1 |
| Pepine, CJ | 1 |
| Cooper-DeHoff, RM | 1 |
| Weiss, RJ | 1 |
| Koren, M | 1 |
| Bittar, N | 1 |
| Thadani, U | 1 |
| Minkwitz, MC | 1 |
| Michelson, EL | 1 |
| Hutchinson, HG | 3 |
| Mehler, PS | 2 |
| Coll, JR | 1 |
| Estacio, R | 1 |
| Esler, A | 2 |
| Schrier, RW | 9 |
| Hiatt, WR | 2 |
| Havranek, EP | 1 |
| Estacio, RO | 8 |
| White, WB | 3 |
| Saunders, E | 1 |
| Noveck, RJ | 1 |
| Ferdinand, K | 1 |
| Benndorf, RA | 4 |
| Rudolph, T | 1 |
| Appel, D | 4 |
| Schwedhelm, E | 4 |
| Maas, R | 4 |
| Schulze, F | 2 |
| Silberhorn, E | 2 |
| Böger, RH | 3 |
| Bajcetic, M | 1 |
| Riekhof, D | 1 |
| Gehling, UM | 1 |
| Schlagner, K | 1 |
| Hossfeld, DK | 1 |
| Rogiers, X | 1 |
| Böger, R | 1 |
| Wenzel, UO | 1 |
| Hall, CE | 1 |
| Hungerford, S | 1 |
| Altura, BM | 1 |
| Altura, BT | 1 |
| Wambach, G | 1 |
| Breuer, G | 1 |
| Kaufmann, W | 1 |
| Davidsson, GK | 3 |
| Edwards, JS | 3 |
| Davidson, C | 3 |
| Lewis, BS | 1 |
| Zimlichman, R | 2 |
| Zilberman, D | 1 |
| Gold, B | 1 |
| Rinaldi, G | 1 |
| Cingolani, H | 1 |
| Ogawa, Y | 2 |
| Ishimitsu, T | 4 |
| Tsukada, H | 2 |
| Yagi, S | 3 |
| Ono, H | 2 |
| Oka, K | 1 |
| Rosenthal, T | 2 |
| Grossman, E | 2 |
| Heinig, R | 4 |
| Muschalek, V | 1 |
| Ahr, G | 2 |
| Blau, A | 2 |
| Herzog, D | 4 |
| Herz, I | 1 |
| Battler, A | 1 |
| Schechter, P | 1 |
| Eliahou, HE | 4 |
| Belousov, IuB | 2 |
| Akhadov, ShV | 1 |
| Volkov, MG | 1 |
| Campbell, SE | 1 |
| Turek, Z | 1 |
| Rakusan, K | 1 |
| Kazda, S | 3 |
| Maruyama, T | 1 |
| Takanohashi, A | 1 |
| Savage, S | 1 |
| Johnson Nagel, N | 1 |
| Feig, PU | 1 |
| MacCarthy, EP | 1 |
| Lukken, NJ | 1 |
| Ziegler, R | 1 |
| Mitchell, J | 1 |
| Frishman, W | 1 |
| Heiman, M | 1 |
| Hoffbrand, BI | 1 |
| Earle, KA | 1 |
| Nievel, JG | 1 |
| Restrick, LJ | 1 |
| Simmonds, NJ | 1 |
| Tavli, T | 1 |
| Kozan, O | 1 |
| Cin, VG | 1 |
| Dogan, A | 1 |
| Gokçin, A | 1 |
| Shionoiri, H | 1 |
| Minamisawa, K | 1 |
| Masumori, S | 1 |
| Satta, H | 1 |
| Minamisawa, M | 1 |
| Takizawa, T | 1 |
| Jinno, Y | 1 |
| Takeda, K | 1 |
| Nagasawa, T | 1 |
| Takasaki, I | 1 |
| Plosker, GL | 1 |
| Faulds, D | 1 |
| Jeffers, B | 1 |
| Rossing, P | 1 |
| Tarnow, L | 1 |
| Boelskifte, S | 1 |
| Jensen, BR | 1 |
| Nielsen, FS | 1 |
| Parving, HH | 1 |
| Opie, LH | 3 |
| Müller, FO | 1 |
| Myburgh, DP | 1 |
| Rosendorff, C | 1 |
| Sareli, P | 3 |
| Seedat, YK | 1 |
| Weich, DJ | 1 |
| Luus, HG | 1 |
| Schaefer, HG | 1 |
| Adelmann, H | 1 |
| Tetzloff, W | 1 |
| Kuhlmann, J | 1 |
| Langan, J | 1 |
| Rodríguez-Mañas, L | 1 |
| Fodor, JG | 2 |
| Ruddy, TD | 1 |
| Jeffers, BW | 2 |
| Biggerstaff, SL | 1 |
| Gifford, N | 2 |
| Cutler, JA | 1 |
| Pahor, M | 2 |
| Psaty, BM | 1 |
| Furberg, CD | 1 |
| Husten, L | 1 |
| Jeffers, ER | 1 |
| Osende, JI | 1 |
| Walker, AM | 1 |
| Molitch, ME | 1 |
| Hoglund, C | 1 |
| Flórez, H | 1 |
| Casanova, P | 1 |
| Minami, J | 1 |
| Higashi, T | 1 |
| Numabe, A | 1 |
| Matsuoka, H | 1 |
| Tatti, P | 1 |
| Radevski, I | 1 |
| Skudicky, D | 1 |
| Candy, G | 1 |
| Sathekge, S | 1 |
| Strugo, V | 1 |
| Smithard, DJ | 1 |
| Mansoor, GA | 1 |
| Pickering, TG | 1 |
| Vidt, DG | 1 |
| Johnson, RB | 1 |
| Noveck, R | 1 |
| Fink, KS | 1 |
| Ellsworth, A | 1 |
| Whitcomb, C | 1 |
| Enzmann, G | 1 |
| Pershadsingh, HA | 1 |
| Johnson, R | 1 |
| Ciuryla, V | 1 |
| Reisin, E | 1 |
| Wellman, GC | 1 |
| Cartin, L | 1 |
| Eckman, DM | 1 |
| Stevenson, AS | 1 |
| Saundry, CM | 1 |
| Lederer, WJ | 1 |
| Nelson, MT | 1 |
| Lenz, TL | 1 |
| Wurdeman, RL | 1 |
| Hilleman, DE | 1 |
| Kanda, A | 1 |
| Haruno, A | 1 |
| Miyake, H | 1 |
| Nagasaka, M | 1 |
| Frohlich, ED | 1 |
| Sasaki, O | 1 |
| Chien, Y | 1 |
| Arita, M | 1 |
| Shechter, P | 2 |
| Sidorenko, GI | 1 |
| Tsybulev, VA | 1 |
| Pavlova, AI | 1 |
| Liventseva, MM | 1 |
| Tsapaev, VG | 1 |
| Belfort, MA | 1 |
| Kirshon, B | 1 |
| Chandler, MH | 1 |
| Clifton, GD | 1 |
| Lettieri, JT | 1 |
| Mazzu, AL | 1 |
| Allington, DR | 1 |
| Thieneman, AC | 1 |
| Foster, TS | 1 |
| Harrison, MR | 1 |
| Ohno, A | 1 |
| Inagaki, C | 1 |
| Honda, K | 1 |
| Sugino, N | 1 |
| Belousov, Y | 1 |
| Kushnaryov, V | 1 |
| Krivonkin, KIu | 1 |
| Clarke, CW | 1 |
| Kubik, MM | 1 |
| Guillén Llera, F | 1 |
| Reuss, JM | 1 |
| Sagués, F | 1 |
| Tobares, N | 1 |
| Pasanisi, F | 2 |
| Soro, S | 1 |
| Ferrara, LA | 1 |
| Tresham, JA | 1 |
| Whitworth, JA | 2 |
| Scoggins, BA | 2 |
| Bennett, WM | 1 |
| Ludwig, J | 1 |
| Gerhardt, T | 1 |
| Halbrügge, T | 1 |
| Walter, J | 1 |
| Heidbreder, E | 1 |
| Graefe, KH | 1 |
| Wahbha, MM | 2 |
| Wilson, J | 3 |
| Hainsworth, R | 2 |
| Ottosson, AM | 1 |
| Karlberg, BE | 1 |
| Smith, JM | 2 |
| Jones, AW | 2 |
| Kiowski, W | 1 |
| Pfisterer, M | 1 |
| Burkart, F | 1 |
| Shimamatsu, K | 1 |
| Garthoff, B | 1 |
| Knorr, A | 1 |
| Giebisch, G | 1 |
| Guckian, VA | 1 |
| Klein-Robbenhaar, G | 1 |
| Klein-Robbenhaar, MT | 1 |
| Lund-Johansen, P | 4 |
| Omvik, P | 4 |
| Haugland, H | 3 |
| Ruilope, LM | 1 |
| Miranda, B | 1 |
| Garcia-Robles, R | 1 |
| Bigorra, J | 1 |
| Oliet, A | 1 |
| Alcazar, JM | 1 |
| Sancho Rof, J | 1 |
| Rodicio, JL | 1 |
| van Harten, J | 1 |
| van Brummelen, P | 1 |
| Danhof, M | 1 |
| Quekel, RP | 1 |
| Breimer, DD | 1 |
| Orchard, MA | 1 |
| Spencer, AA | 1 |
| Davies, JA | 2 |
| Prentice, CR | 2 |
| Spence, CD | 1 |
| Brown, A | 1 |
| Coghlan, JP | 1 |
| Parkes, DG | 1 |
| Rosenfeld, JB | 1 |
| Zabludowski, J | 1 |
| Brigden, G | 1 |
| Heber, M | 1 |
| Caruana, M | 1 |
| Lahiri, A | 1 |
| Raftery, EB | 1 |
| Takahashi, H | 1 |
| Fukuyama, M | 1 |
| Yoneda, S | 1 |
| Okabayashi, H | 1 |
| Yoshimura, M | 1 |
| Kuwajima, I | 1 |
| Kaneko, Y | 1 |
| Takeda, T | 1 |
| Martin, PG | 1 |
| Brownjohn, AM | 1 |
| Turney, JH | 1 |
| Cragoe, EJ | 1 |
| Iimura, O | 1 |
| Kikuchi, K | 1 |
| Shimamoto, K | 1 |
| Nozawa, A | 1 |
| Hasegawa, R | 1 |
| Homma, C | 1 |
| Komura, H | 1 |
| Kobayakawa, H | 1 |
| Nayler, WG | 1 |
| Dillon, JS | 1 |
| Sturrock, WJ | 1 |
| Stasch, JP | 1 |
| Hirth, C | 1 |
| Morich, F | 1 |
| Friedel, HA | 1 |
| Sorkin, EM | 1 |
| Ramsay, LE | 1 |
| Waller, PC | 1 |
| Cohen, D | 2 |
| Serban, I | 2 |
| Kapuler, S | 2 |
| Schiby, G | 1 |
| Gavendo, S | 2 |
| Ben-David, A | 1 |
| Kogan, N | 1 |
| Hellberg, B | 1 |
| Karasawa, A | 1 |
| Kubo, K | 1 |
| Oka, T | 1 |
| Nakamizo, N | 1 |
| Tasaka, K | 1 |
| Kamei, C | 1 |
| Tagami, H | 1 |
| Hokonohara, T | 1 |
| Sugimoto, Y | 1 |
| Deeg, P | 1 |
| Weiss, KH | 1 |
| Schmitz, H | 1 |
| Daniels, AR | 1 |
| Meredith, PA | 1 |
| Reid, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for nisoldipine and Blood Pressure, High
| Article | Year |
|---|---|
The RAAS in the pathogenesis and treatment of diabetic nephropathy.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2010 |
Pharmacologic agents in the management of hypertension--nisoldipine coat-core.
Topics: Antihypertensive Agents; Black or African American; Black People; Blood Pressure; Calcium Channel Bl | 2007 |
Microcirculatory actions and uses of naturally-occurring (magnesium) and novel synthetic calcium channel blockers.
Topics: Anesthesia; Animals; Arterioles; Blood Pressure; Calcium; Calcium Channel Blockers; Cell Membrane Pe | 1984 |
Efficacy and safety of nisoldipine coat core in the management of angina pectoris, systemic hypertension, and ischemic ventricular dysfunction.
Topics: Angina Pectoris; Delayed-Action Preparations; Humans; Hypertension; Myocardial Infarction; Nisoldipi | 1995 |
Nisoldipine: a new dihydropyridine calcium-channel blocker.
Topics: Angina Pectoris; Cardiovascular Diseases; Heart Rate; Hemodynamics; Humans; Hypertension; Nisoldipin | 1993 |
Nisoldipine coat-core. A review of its pharmacology and therapeutic efficacy in hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Drug Ca | 1996 |
Nisoldipine CC: clinical experience in hypertension.
Topics: Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Delayed-Action Preparations; Humans | 1997 |
Nisoldipine CC: efficacy and tolerability in hypertension and ischemic heart disease.
Topics: Aging; Angina Pectoris; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Delayed-A | 1997 |
What does nisoldipine coat core (CC) add to current therapy that is clinically meaningful?
Topics: Blood Pressure; Calcium Channel Blockers; Delayed-Action Preparations; Humans; Hypertension; Hypertr | 1997 |
Clinical pharmacokinetics of nisoldipine coat-core.
Topics: Age Factors; Antihypertensive Agents; Calcium Channel Blockers; Delayed-Action Preparations; Drug In | 1998 |
[Clinical pharmacology of nisoldipine, a new calcium antagonist].
Topics: Angina Pectoris; Animals; Cardiovascular Diseases; Drug Interactions; Humans; Hypertension; Nisoldip | 1991 |
Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders.
Topics: Angina Pectoris; Calcium Channel Blockers; Cardiovascular Diseases; Humans; Hypertension; Nifedipine | 1988 |
55 trials available for nisoldipine and Blood Pressure, High
| Article | Year |
|---|---|
Effect of nisoldipine and olmesartan on endothelium-dependent vasodilation in essential hypertensive patients.
Topics: Aged; Anthracenes; Antihypertensive Agents; Arginine; Blood Pressure; C-Reactive Protein; Case-Contr | 2012 |
Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus.
Topics: Adult; Antihypertensive Agents; Area Under Curve; Biomarkers; Blood Glucose; Blood Pressure; Cross-O | 2002 |
Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris.
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Delayed-Action Preparations; Double-Blind Met | 2003 |
Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes.
Topics: Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Cohort Studies; Comorbidity; Death | 2003 |
Differential effects of antihypertensive agents on electrocardiographic voltage: results from the Appropriate Blood Pressure Control in Diabetes (ABCD) trial.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, T | 2003 |
Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Black or African American; Blood Pressure; Blood P | 2003 |
Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.
Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2006 |
Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension.
Topics: Administration, Oral; Aged; Angiotensin II Type 1 Receptor Blockers; Area Under Curve; Benzimidazole | 2007 |
Mobilization of putative high-proliferative-potential endothelial colony-forming cells during antihypertensive treatment in patients with essential hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antigens, CD; Antihypertens | 2007 |
Telmisartan improves endothelial function in patients with essential hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; B | 2007 |
[Hypotensive properties of nisoldipine. Comparative study in essential, renal and renovascular hypertension].
Topics: Adult; Aged; Aldosterone; Calcium Channel Blockers; Electrolytes; Female; Heart Rate; Humans; Hydroc | 1984 |
The effect of age and liver disease on the pharmacokinetics of the calcium antagonist, nisoldipine.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Calcium Channel Blockers; Edema; | 1995 |
Acute hemodynamic effects of nisoldipine in young hypertensive patients.
Topics: Adult; Age Factors; Blood Pressure; Cardiography, Impedance; Double-Blind Method; Heart Rate; Hemody | 1995 |
[The comparative effect of calcium antagonists on hemodynamics in patients with a stable form of essential hypertension (a randomized study)].
Topics: Calcium Channel Blockers; Diltiazem; Dose-Response Relationship, Drug; Hemodynamics; Humans; Hyperte | 1994 |
The ABCD (Appropriate Blood Pressure Control in Diabetes) trial. Rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes.
Topics: Adult; Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Enalapril; Female | 1993 |
Comparison of nisoldipine and nifedipine as additional treatment in hypertension inadequately controlled by atenolol.
Topics: Atenolol; Black People; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension | 1993 |
Pharmacokinetics and pharmacodynamics of nisoldipine in hypertensive patients with normal and mild to moderate impaired renal function.
Topics: Blood Pressure; Female; Half-Life; Heart Rate; Humans; Hypertension; Kidney Diseases; Male; Middle A | 1995 |
Comparison of once daily and twice daily nisoldipine as monotherapy in essential hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dose-Response Relationship | 1996 |
Appropriate Blood Pressure Control in NIDDM (ABCD) Trial.
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel | 1996 |
Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressur | 1997 |
Efficacy and tolerability of nisoldipine coat-core formulation in the treatment of essential hypertension: The South African Multicenter ANCHOR Study. Ambulatory Nisoldipine Coat-Core Hypertension Outpatient Response (ANCHOR) Investigators.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 1997 |
Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form.
Topics: Adult; Blood Pressure; Calcium Channel Blockers; Delayed-Action Preparations; Female; Food-Drug Inte | 1997 |
Nisoldipine CC and lisinopril alone or in combination for treatment of mild to moderate systemic hypertension. Canadian Nisoldipine CC Hypertension Trial Group.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Blood Pressure Mo | 1997 |
The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiovascular Dise | 1998 |
A comparison of nisoldipine coat-core and felodipine in the treatment of mild-to-moderate hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Double-Blind Method; Edema; Felodipine; Female; Humans; Hypert | 1998 |
Comparison between cilnidipine and nisoldipine with respect to effects on blood pressure and heart rate in hypertensive patients.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Bloc | 1998 |
Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Cha | 1998 |
The Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET) and combination therapies.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1999 |
Antihypertensive monotherapy with nisoldipine CC is superior to enalapril in black patients with severe hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Black People; Blood Pressure; Blood Pressure Monitoring, A | 1999 |
A comparison of once daily versus twice daily nisoldipine as monotherapy in patients over 65 years of age.
Topics: Aged; Blood Pressure; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypertensio | 1994 |
Differential effects of morning and evening dosing of nisoldipine ER on circadian blood pressure and heart rate.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Cr | 1999 |
Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Ty | 2000 |
A comparison of nisoldipine ER and amlodipine for the treatment of mild to moderate hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Determination; Delayed-Action Prepa | 2000 |
Comparison of 24-hour blood pressure profiles in patients with hypertension who were switched from amlodipine to nisoldipine.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Bloc | 2001 |
Effect of nisoldipine on ambulatory blood pressure under 24-hour noninvasive monitoring.
Topics: Adult; Aged; Ambulatory Care; Blood Pressure; Blood Pressure Monitors; Circadian Rhythm; Diastole; F | 1992 |
Nisoldipine--a new orally administered calcium antagonist used in the treatment of severe postpartum pregnancy-induced hypertension. Preliminary results.
Topics: Blood Pressure; Female; Heart Rate; Humans; Hypertension; Nisoldipine; Pilot Projects; Pregnancy; Pu | 1992 |
Multiple dose pharmacokinetics of four different doses of nisoldipine in hypertensive patients.
Topics: Adult; Aged; Chemistry, Pharmaceutical; Delayed-Action Preparations; Double-Blind Method; Drug Admin | 1992 |
The effects of nisoldipine, diltiazem, nifedipine, and verapamil on hemodynamic parameters and red blood cells-platelet interactions in patients with arterial hypertension.
Topics: Adult; Aged; Arteries; Blood Platelets; Blood Pressure; Calcium Channel Blockers; Diltiazem; Erythro | 1991 |
Nifedipine and nisoldipine in hypertensive diabetics.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Diabetes Complications; Diabetes Mellitus; Humans; Hyper | 1991 |
[A comparative study of nisoldipine and alpha-methyldopa in aged patients with isolated systolic hypertension].
Topics: Age Factors; Aged; Aged, 80 and over; Female; Humans; Hypertension; Male; Methyldopa; Nisoldipine; S | 1991 |
Responses to sympathetic stimulation and tilting during antihypertensive treatment with nisoldipine.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cold Temperature; Exercise; Female; Heart Rate; H | 1991 |
Effects of nisoldipine on stress-induced changes in haemodynamics and plasma catecholamines in normotensives and hypertensives.
Topics: Adult; Blood Pressure; Catecholamines; Dopamine; Double-Blind Method; Epinephrine; Exercise; Female; | 1990 |
Nisoldipine--effects on the renin-angiotensin-aldosterone system and catecholamines. Studies in normotensive and hypertensive subjects.
Topics: Angiotensin II; Epinephrine; Female; Humans; Hypertension; Male; Middle Aged; Nisoldipine; Norepinep | 1990 |
Central hemodynamic changes of calcium antagonists at rest and during exercise in essential hypertension.
Topics: Adult; Calcium Channel Blockers; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Nife | 1987 |
Anti-hypertensive drugs non-specifically reduce "spontaneous" activation of blood platelets.
Topics: Adult; Aged; Antihypertensive Agents; beta-Thromboglobulin; Double-Blind Method; Drug Evaluation; Fe | 1989 |
The efficacy and tolerability of nifedipine (NIF) and nisoldipine (NIS) both alone and combined with a beta-blocker in patients with essential hypertension: a multicenter, parallel-group study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Body Weight; Double-Blind Method; Drug The | 1989 |
Comparison of nisoldipine and atenolol in the treatment of essential hypertension.
Topics: Adult; Aged; Atenolol; Blood Pressure; Calcium Channel Blockers; Captopril; Heart Rate; Humans; Hype | 1989 |
[Age and efficacy of new long acting calcium blocker, nisoldipine, is essential hypertension].
Topics: Adult; Age Factors; Aged; Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials as Topi | 1989 |
The effect of nisoldipine on renal function in the long-term treatment of hypertension in patients with and without renal impairment.
Topics: Adult; Aged; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind Method | 1989 |
Rapid development of tolerance to the antihypertensive effect of nisoldipine.
Topics: Adolescent; Adult; Aged; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Double- | 1988 |
The calcium channel blocker nisoldipine delays progression of chronic renal failure in humans (preliminary communication).
Topics: Adult; Blood Pressure; Calcium Channel Blockers; Dietary Proteins; Follow-Up Studies; Humans; Hypert | 1988 |
Nisoldipine. Central haemodynamics at rest and during exercise in essential hypertension: acute and chronic studies.
Topics: Adult; Calcium Channel Blockers; Cardiac Output; Female; Hemodynamics; Humans; Hypertension; Male; N | 1988 |
[Nisoldipine in the treatment of essential hypertension. Efficacy and tolerance].
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; | 1987 |
Monotherapy with the calcium channel antagonist nisoldipine for systemic hypertension and comparison with diuretic drugs.
Topics: Adult; Amiloride; Calcium Channel Blockers; Diuretics; Dose-Response Relationship, Drug; Double-Blin | 1987 |
The pharmacodynamics and pharmacokinetics of a new calcium antagonist nisoldipine in normotensive and hypertensive subjects.
Topics: Adult; Blood Pressure; Calcium Channel Blockers; Humans; Hypertension; Kinetics; Male; Nifedipine; N | 1985 |
54 other studies available for nisoldipine and Blood Pressure, High
| Article | Year |
|---|---|
Enhanced bioavailability and antihypertensive activity of nisoldipine loaded nanoemulsion: optimization, cytotoxicity and uptake across Caco-2 cell line, pharmacokinetic and pharmacodynamic studies.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Biological Availability; Caco-2 Cells; Disea | 2020 |
Gingival hyperplasia in a patient with hypertension.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Female; Gingival Hyperplasia; Humans; Hypertensio | 2008 |
Prevention of spontaneous and glucocorticoid hypertension in rats by nisoldipine.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Cortisone; Glucocorticoids; Hypertension; Male; N | 1983 |
Relationship between baseline blood pressure and blood pressure decrease after calcium channel blockers in conscious rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Consciousness; Hypertens | 1994 |
Benefits and demerits of antihypertensive therapy by high-dose calcium channel blocker in severely hypertensive rats.
Topics: Animals; Antihypertensive Agents; Aorta; Body Weight; Calcium Channel Blockers; Cardiomegaly; Dose-R | 1994 |
Renoprotective effect of nisoldipine in rats with severe hypertension.
Topics: Animals; Aorta; Arterioles; Atenolol; Blood Pressure; Creatinine; Desoxycorticosterone; Enalapril; H | 1994 |
Nisoldipine for hypertension.
Topics: Animals; Disease Models, Animal; Humans; Hypertension; Hypertension, Renovascular; Nisoldipine; Rats | 1994 |
Determination of the enantiomers of nisoldipine in human plasma using high-performance liquid chromatography on a chiral stationary phase and gas chromatography with mass-selective detection.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Deuterium; Female; Humans; Hypertension; Liver Ci | 1994 |
Cardiovascular effects of nisoldipine in essential hypertension.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cardiac Output; Female; Heart Rate; Hemodynamics; | 1994 |
Nisoldipine--is there a positive inotropic effect?
Topics: Cardiac Output; Humans; Hypertension; Myocardial Contraction; Nisoldipine; Stimulation, Chemical | 1994 |
Cardiac structural remodelling after treatment of spontaneously hypertensive rats with nifedipine or nisoldipine.
Topics: Animals; Cell Size; Fibrosis; Heart; Hypertension; Male; Myocardium; Nifedipine; Nisoldipine; Organ | 1993 |
[Effects of nisoldipine in heminephrectomized spontaneously hypertensive rats--measurement of afferent and efferent arterioles by microvascular cast].
Topics: Animals; Arterioles; Blood Pressure; Hypertension; Kidney Glomerulus; Male; Microscopy, Electron, Sc | 1993 |
The effects of nisoldipine on carotid artery stiffness and left ventricular functions.
Topics: Adult; Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Calcium Channel Blockers; Carot | 1995 |
Nisoldipine--a new calcium channel blocker for hypertension.
Topics: Animals; Antihypertensive Agents; Calcium Channel Blockers; Humans; Hypertension; Nisoldipine | 1996 |
JNC VI guidelines.
Topics: Antihypertensive Agents; Enalapril; Humans; Hypertension; Nisoldipine; Research Design | 1998 |
Calcium-channel blockers for hypertension--uncertainty continues.
Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiovascular Diseases; Diabete | 1998 |
Treatment of hypertensive patients with diabetes.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1998 |
Calcium antagonist stopped in ABCD study. Appropriate Blood Pressure Control in Diabetes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Clinica | 1998 |
Study poses new questions about calcium-channel blockers.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Diabetes Complications; Humans; Hypertension; Nis | 1998 |
Calcium blockers questioned.
Topics: Calcium Channel Blockers; Diabetes Mellitus, Type 2; Humans; Hypertension; Myocardial Infarction; Ni | 1998 |
Diabetes and blood pressure drugs.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Diabetes Complicati | 1998 |
Nisoldipine and myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Enala | 1998 |
Nisoldipine and myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Enala | 1998 |
Nisoldipine and myocardial infarction.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Diabetes Mellitus, | 1998 |
[Changes in clinical intervention studies: when the wellbeing of the patients takes precedence].
Topics: Antihypertensive Agents; Chromans; Clinical Trials as Topic; Diabetes Complications; Enalapril; Ethi | 1998 |
Antihypertensive treatment and CHD in the elderly.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; | 1999 |
Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiovascular Diseases; Diabete | 2000 |
Membrane depolarization, elevated Ca(2+) entry, and gene expression in cerebral arteries of hypertensive rats.
Topics: Animals; Calcium; Calcium Channel Blockers; Calcium Channels; Cerebral Arteries; Cyclic AMP Response | 2001 |
[Blood pressure amplitude in the morning must be reduced. Saving the hypertensive patient from infarct].
Topics: Aged; Blood Pressure; Calcium Channel Blockers; Cerebral Infarction; Circadian Rhythm; Clinical Tria | 2002 |
Antihypertensive effects of MPC-1304, a novel calcium antagonist, in experimental hypertensive rats and dogs.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Co | 1992 |
Changes in cardiovascular mass, left ventricular pumping ability and aortic distensibility after calcium antagonists in Wistar-Kyoto and spontaneously hypertensive rats.
Topics: Animals; Aorta; Compliance; Heart; Heart Ventricles; Hemodynamics; Hypertension; Male; Nifedipine; N | 1992 |
[Clinical effectiveness and effect on the sympathetic-adrenal system of a new calcium antagonist nisoldipine (Siscor) in hypertensive patients].
Topics: Catecholamines; Hemodynamics; Humans; Hypertension; Nisoldipine; Sympathetic Nervous System; Treatme | 1992 |
Comparison of converting enzyme inhibitor and calcium channel blocker in SHR with nephrotoxic serum nephritis.
Topics: Analysis of Variance; Animals; Antibodies, Heterophile; Basement Membrane; Captopril; Glomerulonephr | 1992 |
The failure of nisoldipine to prevent the hypertensive response to cyclosporine A infusion in sheep.
Topics: Animals; Calcium; Cyclosporins; Drinking; Eating; Female; Glomerular Filtration Rate; Hemodynamics; | 1990 |
Cardiovascular responses to upright tilting in hypertensive patients, with and without renal impairment and before and following nisoldipine treatment.
Topics: Adult; Blood Pressure; Cardiac Output; Female; Heart Rate; Hemodynamics; Humans; Hypertension; Kidne | 1990 |
Calcium antagonists inhibit elevated potassium efflux from aorta of aldosterone-salt hypertensive rats.
Topics: Aldosterone; Animals; Aorta; Calcium; Calcium Channel Blockers; Diltiazem; Hypertension; In Vitro Te | 1990 |
Direct vascular and myocardial effects of nisoldipine.
Topics: Adult; Aged; Blood Pressure; Brachial Artery; Cardiac Output; Coronary Vessels; Female; Heart; Human | 1990 |
Diastolic blood pressure and progression of chronic renal failure.
Topics: Diastole; Glomerulonephritis; Humans; Hypertension; Kidney Failure, Chronic; Myocardial Contraction; | 1990 |
Interference of the calcium antagonist nisoldipine with the abnormal response of vessels from hypertensive rats to alpha-adrenergic stimulation.
Topics: Adrenergic alpha-Agonists; Animals; Azepines; Hypertension; In Vitro Techniques; Male; Muscle Contra | 1985 |
Renal clearance and micropuncture studies of nisoldipine effects in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Glomerular Filtration Rate; Hypertension; Kidney; | 1987 |
Central hemodynamic effects at rest and during exercise of acute and chronic treatment with nisoldipine in essential hypertension.
Topics: Adult; Blood Pressure; Calcium Channel Blockers; Cardiac Output; Female; Heart Rate; Hemodynamics; H | 1987 |
Effects of nisoldipine on renal function in normal volunteers and essential hypertensive patients.
Topics: Adult; Blood Pressure; Body Weight; Diet, Sodium-Restricted; Glomerular Filtration Rate; Humans; Hyp | 1989 |
Pharmacokinetics and hemodynamic effects of long-term nisoldipine treatment in hypertensive patients.
Topics: Administration, Oral; Aged; Calcium Channel Blockers; Child; Hemodynamics; Humans; Hypertension; Inf | 1989 |
Rapid haemodynamic response to adrenocorticotrophin and the role of peripheral resistance in adrenocorticotrophin-induced hypertension in conscious sheep.
Topics: Adrenocorticotropic Hormone; Animals; Calcium Channel Blockers; Consciousness; Female; Hemodynamics; | 1989 |
Once daily nisoldipine in hypertension: cuff and ambulatory intra-arterial blood pressure.
Topics: Adult; Aged; Ambulatory Care; Blood Pressure; Blood Pressure Determination; Dose-Response Relationsh | 1989 |
Nisoldipine inhibition of sodium influx into aorta from aldosterone-salt-hypertensive rats.
Topics: Aldosterone; Animals; Aorta; Calcium; Calcium Channel Blockers; Hydrogen; Hypertension; Ion Exchange | 1989 |
Effects of nisoldipine on sympathetic activity, the renin-angiotensin-aldosterone system, and water-sodium-calcium metabolism in patients with essential hypertension.
Topics: Adult; Aged; Blood Pressure; Calcium; Calcium Channel Blockers; Creatinine; Female; Humans; Hyperten | 1989 |
Calcium antagonists and hypertension.
Topics: Aging; Aniline Compounds; Animals; Blood Pressure; Calcium Channel Blockers; Catecholamines; Dihydro | 1988 |
Role of nisoldipine on blood pressure, cardiac hypertrophy, and atrial natriuretic peptides in spontaneously hypertensive rats.
Topics: Animals; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Hypertension; Male; Nifedipine; Ni | 1987 |
The control of hypertension and its effect on renal function in rat remnant kidney.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Creatinine; Dietary Proteins; Dihydralazine; Fema | 1988 |
Antihypertensive effects of intravenous administration of benidipine hydrochloride and some other calcium antagonists in conscious, spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diltiazem; Dose-Response | 1988 |
Antihypertensive effects of nisoldipine and reference drugs in certain types of hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Desoxycorticosterone; Hypertension; Hypertension, | 1987 |
Nisoldipine: a replacement therapy for nifedipine in the treatment of severe hypertension.
Topics: Adult; Aged; Blood Pressure; Calcium Channel Blockers; Female; Humans; Hypertension; Male; Middle Ag | 1988 |
Acute and chronic hemodynamic effects of nisoldipine in essential hypertension at rest and during exercise.
Topics: Female; Hemodynamics; Humans; Hypertension; Male; Nifedipine; Nisoldipine; Physical Exertion | 1986 |